A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer.

Cancer chemotherapy and pharmacology

Volumn 71, Issue 4, 2013, Pages 973-979

  Sasaki, Takashi ^a   Isayama, Hiroyuki ^b   Nakai, Yousuke ^b   Ito, Yukiko ^b   Yasuda, Ichiro ^b   Toda, Nobuo ^b   Kogure, Hirofumi ^b   Hanada, Keiji ^b   Maguchi, Hiroyuki ^b   Sasahira, Naoki ^b   Kamada, Hideki ^b   Mukai, Tsuyoshi ^b   Okabe, Yoshihiro ^b   Hasebe, Osamu ^b   Maetani, Iruru ^b   Koike, Kazuhiko ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; OTERACIL; S 1 (COMBINATION); TEGAFUR;

AGED; ARTICLE; BILIARY TRACT TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; DEOXYCYTIDINE; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PATIENT COMPLIANCE; TEGAFUR;

EID: 84878838680     PISSN: None     EISSN: 14320843     Source Type: None    
DOI: 10.1007/s00280-013-2090-4     Document Type: Article

References (0)